Mace

(redirected from Major Adverse Cardiac Events)
Also found in: Dictionary, Thesaurus, Financial, Acronyms, Encyclopedia.

Mace

 [mās]
trademark for an aerosol mixture of CS, a common tear gas.

Mace

, MACE (mās),
Acronym for methylchloroform 2-chloracetophenone (the prototypical lacrimator) in a light petroleum dispersant and a pressurized propellant.

mace

[mās]
the oil-containing, red, fibrous wrapping of the nutmeg kernel. Dried and ground, it is used as an aromatic spice and flavoring. Historical medicinal uses include the treatment of gastrointestinal disorders and as an analgesic; however, there are no clinical trials supporting its effectiveness. Compare Mace.

Mace

a trademark for a chemical agent that causes tearing and eye pain. The name is an abbreviation formed by letters in methylchloroform-2-chloroacetophenone, which is dispersed from a pressurized container to immobilize an attacker.
An acronym for objective measures of acute and/or adverse cardiovascular events (e.g., acute myocardial infarction, ischaemic stroke, coronary arterial occlusion, death) which are used to assess the effects of various interventions (e.g., rotablation, angioplasty, stenting) or therapeutics (e.g., antiarrhythmics, statins, ACE inhibitors) on outcomes, in the context of a clinical trial.

Mace

A tear gas made from the lacrimatory agent chloracetophenone combined with a dispersant and an aerosol propellant.
References in periodicals archive ?
In the important clinical endpoint of MACE, one-year follow-up results from 300 patients enrolled in Abbott's randomized SPIRIT II European clinical trial demonstrated superiority for XIENCE V compared to TAXUS in an additional analysis with a statistically significant 71 percent reduction in major adverse cardiac events for XIENCE V-treated patients compared to TAXUS-treated patients (2.
6% rate in those who got BMSs), the overall rate of major adverse cardiac events was not significantly different between the two groups: 15.
For them the committee recommended adding transmyocardial revascularization to improve the likelihood of long-term angina relief (up to 5 years), reduce 30-day mortality and major adverse cardiac events, and improve 1-year exercise performance.
For them the committee recommended adding trans myocardial revascularization to improve the likelihood of long-term angina relief (up to 5 years), reduce 30-day mortality and major adverse cardiac events, and improve 1-year exercise performance.
Results showed no acute myocarditis attributable to CAP-1002, no death due to ventricular tachycardia (VT) or ventricular fibrillation (VF), no sudden death and no major adverse cardiac events.
For the endpoint of major adverse cardiac events (MACE) at two years, which is a composite of all death, non-fatal heart attack (myocardial infarction or MI) and target vessel revascularisation (TVR), XIENCE V showed a 34% lower incidence of MACE compared to TAXUS (9% for XIENCE V vs.
There was a consistent trend for fewer major adverse cardiac events with the Cypher, compared with the Taxus DES; however, the sample size was too small to determine statistical significance.
The primary efficacy endpoint of the trial is a time-to-first event analysis of heart failure-related Major Adverse Cardiac Events (HFMACE), defined as a composite of cardiac related death or resuscitated cardiac death, or non-fatal decompensated heart failure events.

Full browser ?